Ultragenyx Pharmaceutical Inc. (RARE) CLO sells 1,900 shares at $24.92
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. EVP and Chief Legal Officer Karah Herdman Parschauer reported a sale of 1,900 shares of common stock on August 3, 2026 at $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including previously reported RSU-based shares subject to vesting conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 1,900 shares
Net Sell
1 txn
Insider
Parschauer Karah Herdman
Role
EVP and Chief Legal Officer
Sold
1,900 shs ($47K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 1,900 | $24.92 | $47K |
Holdings After Transaction:
Common Stock — 92,562 shares (Direct)
Footnotes (1)
- F1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Key Figures
Shares sold: 1,900 shares
Sale price: $24.92 per share
Shares held after transaction: 92,562 shares
3 metrics
Shares sold
1,900 shares
Common stock sale on August 3, 2026
Sale price
$24.92 per share
Consideration for the 1,900 shares sold
Shares held after transaction
92,562 shares
Direct holdings following the reported sale, including RSU-based shares
Key Terms
RSUs, vesting conditions, Common Stock
3 terms
RSUs financial
"shares of common stock underlying RSUs granted to the Reporting Person"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vesting conditions financial
"RSUs granted to the Reporting Person, which are subject to certain vesting conditions"
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
Common Stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Ultragenyx (RARE) report for Karah Herdman Parschauer?
Ultragenyx reported that EVP and Chief Legal Officer Karah Herdman Parschauer sold 1,900 shares of common stock on August 3, 2026 at $24.92 per share in an open-market or private transaction.
Was the Ultragenyx (RARE) insider sale made under a Rule 10b5-1 plan?
Yes. The filing indicates the transaction was conducted under a Rule 10b5-1 trading plan, meaning the sale followed a pre-arranged schedule rather than being initiated at the insider’s discretion.
Does the Ultragenyx (RARE) filing mention restricted stock units (RSUs)?
Yes. A footnote states that the 92,562 post-transaction shares include previously reported shares underlying RSUs granted to the reporting person, which are subject to vesting conditions.